Viking Therapeutics Interest Expense 2011-2026 | VKTX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Viking Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
33.7 M	41 M	14.9 M	1.49 M	692 K	3.17 M	6.91 M	4.1 M	-1.51 M	-885 K	-11.4 M	1.58 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
41 M	-11.4 M	7.81 M

Quarterly Interest Expense Viking Therapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9.01 M	9.84 M	-	11.6 M	11.8 M	6.72 M	-	4.73 M	4.52 M	1.01 M	-	423 K	199 K	142 K	-	160 K	160 K	218 K	-	555 K	1.03 M	1.26 M	-	1.71 M	1.9 M	1.88 M	-	794 K	253 K	24 K	-	-1.41 M	-189 K	-253 K	-	-543 K	-115 K	-320 K	-	-448 K	-5.24 M	35.3 K	-	887 K	-1.03 M	2.58 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
11.8 M	-5.24 M	1.75 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	14.2 M	$ 91.4	1.15 %	$ 22.1 B	Germany
Autolus Therapeutics plc AUTL	36.7 M	$ 1.66	2.21 %	$ 442 M	Britain
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Compugen Ltd. CGEN	281 K	$ 2.65	-2.22 %	$ 248 M	Israel
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.4	2.41 %	$ 5.6 M	Israel
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	9 M	$ 1.6	5.63 %	$ 187 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 20.95	2.34 %	$ 2.67 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA